Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 25, 2007

View Archived Issues

Snapshots of dipeptidyl peptidase IV inhibitors from the EASD annual meeting

Survival benefit seen with picoplatin in small cell lung cancer patients

PTC-299 reduces growth of breast cancer xenografts

HE-3235 inhibits growth of MNU-induced breast tumors in rats

Recent Eisai patent reports new antipruritic agents for atopic dermatitis

Recent FibroGen patent discloses novel HIF prolyl hydroxylase inhibitors

5-HT4 receptor agonists: potential antidepressant agents with a rapid onset of action

Alba Therapeutics commences phase IIb trial of oral AT-1001 for celiac disease

NCI-sponsored trials broaden clinical development of ImClone Systems' IMC-A12

Inhibitex broadens pipeline with acquisition of FermaVir

Callisto completes patient enrollment in phase II atiprimod trial

NV1FGF angiogenesis therapy enters phase III clinical evaluation

CHDI to evaluate potential of Intellect Neuroscience's Oxigon in Huntington's disease

Wyeth discontinues development of LXR regulator

Immtech's pafuramidine granted FDA orphan drug status in African sleeping sickness

Update on Teva's edratide in systemic lupus erythematosus

Antibodies with therapeutic potential enter preclinical evaluation at Xencor

Cobiprostone tested in phase II trial for prevention of NSAID-induced ulcers in arthritis patients

Patient enrollment completed in Medicure's pivotal phase III MED-CABG II trial

FDA requires further clinical study on Alcon's Retaane suspension for wet AMD

BioCryst's peramivir does not reach primary endpoint in phase II influenza trial

Novel small molecule from Enzo protects against periodontitis-associated bone loss

CHMP issues positive opinion for Onyx and Bayer's Nexavar for HCC

Cephalon submits Treanda NDA for CLL to FDA

Merck and HVTN discontinue clinical trials of HIV vaccine V-520

Sigma 1 receptor blockade mediates the antiamnesic effects of Anavex 1-41

EC approves Pfizer's CCR5 antagonist and oral entry inhibitor Celsentri

CHMP issues positive opinion for Merck Serono's Cyanokit for cyanide poisoning

European Commission approves once-daily Exelon patch for Alzheimer's disease

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...